Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) was the target of a significant decline in short interest in August. As of August 15th, there was short interest totalling 18,200 shares, a decline of 89.5% from the July 31st total of 172,900 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,060,000 shares, the days-to-cover ratio is presently 0.0 days.

Bone Biologics Stock Down 1.3 %

Shares of BBLG stock opened at $1.54 on Wednesday. Bone Biologics has a 1-year low of $1.00 and a 1-year high of $10.56. The stock has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $1.88.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.39) by $0.72. Analysts expect that Bone Biologics will post -5.32 EPS for the current year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.